Completed
AL Amyloidosis Diagnosis
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
Updates on AL Amyloidosis Treatment - What is New in 2023
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 Amyloidoses-Basic Concepts
- 3 AL Amyloidosis is a Plasma Cell Disorder
- 4 AL Amyloidosis Pathogenesis is Entirely Related to Immunoglobulin Free Light Chain (FLC) Deposition
- 5 Pathophysiology
- 6 "Stickiness" Dictates Rapidity of Overt Clinical Presentation
- 7 AL Amyloidosis Diagnosis
- 8 Cardiac Biopsy -H&E
- 9 Cardiac Biopsy - Congo Red
- 10 Renal Biopsy -Immunofluorescence
- 11 Renal Biopsy-Electron Microscopy
- 12 Cardiac Involvement is the Single Most Important Prognostic Factor in AL Amyloidosis
- 13 Progressive Improvement in OS in AL Amyloidosis
- 14 Diagnostic and Therapeutic Considerations
- 15 Heme Response Criteria in AL Amyloidosis: the Impact of Deep FLC Suppression
- 16 Therapeutic Approach to Newly Diagnosed AL Amyloidosis Patients
- 17 The Andromeda Study: DaraCyBorD versus CyBorD in Newly Diagnosed AL Amyloidosis
- 18 Andromeda: Patient Characteristics
- 19 Superior Hematologic and Organ Response for DaraCyBorD..
- 20 Cardiac Response Impact OS in AL Amyloidosis
- 21 Graded Cardiac Response Criteria -2022
- 22 Complete Cardiac Response Can Potentially Reverse Dismal Outcome of Stage IIIB Patients
- 23 Lack of cardiac response and less than VGPR increase risk of cardiac progression
- 24 Pan Amyloid Antibody AT-01 to Detect Amyloid Deposition Across the Entire Body
- 25 Florbetapir for Early Cardiac Amyloidosis Diagnosis
- 26 T(11;14) is the Most Common Cytogenetic Abnormality in AL Amyloidosis, an Adverse Prognostic Factor and a Negative Predict Factor of Response to Bortezomib
- 27 T(11;14) is a Predictive Biomarker of Response to Venetoclax in MM
- 28 Venetoclax-based Treatment in AL Amyloidosis Appears Effective in t(11;14)
- 29 BCMA is a Highly Expressed Protein on the Surface of Plasma Cells and an Ideal Target for Immune- and Cellular Therapies
- 30 BCMA Bispecific T-cell Engagers (BITEs)
- 31 Teclisimab - the First BITE Approved for Multiple Myeloma
- 32 BCMA CAR-T Cell in AL Amyloidosis
- 33 CAEL-101, a MoAb Specific to Misfolded FLC, Elicits Cardiac Response in AL Amyloidosis
- 34 Pan Amyloid-Targeting Strategies in the Pipeline
- 35 The rationale behind combining anti-fibrillary MoAbs and Chemotherapy
- 36 Our Pledge at the BWH/DFCI Amyloid Program
